
At Bavarian Biotech, we support academic researchers in oncology and drug development by offering services that use MAA (Molecular Affinity Analysis) for preclinical research and translational studies. MAA allows for in situ detection of therapeutically relevant regions and quantification of therapeutic binding site availability, supporting researchers working with preclinical models, patient derived xenografts, and novel drug candidates.
Target Validation & Drug Development
Preclinical Model Optimization
Explore Tumor Heterogeneity
Predicting Drug Efficacy & Resistance Mechanisms
Companion Biomarker Discovery
Molecular Affinity Analysis (MAA) offers a wide range of applications for your preclinical and translational research projects.
Our services include:
binding site density in preclinical models or primary tumor samples.
We invite you to connect with us to explore how our Molecular Affinity Analysis (MAA) platform can address your research and clinical objectives. Whether your focus is on enhancing clinical trial strategies, or advancing therapeutic profiling, our team is ready to provide tailored support and expert guidance.
Contact us to discuss your specific needs, request detailed information, or learn more about how MAA technology can contribute to your success in drug development and precision oncology.